Non-Viral CRISPR Knock-In Anti-B7-H3 CAR-T Cells Are Amenable for Treatment of Subtypes of Small Cell Lung Cancer

In this webinar, Scientist Vimal Keerthi discusses his work on identifying CD276 (B7-H3) overexpression in primary human SCLC and developing a non-viral CRISPR-Cas9 knock-in (CKI) based platform against B7-H3 to manufacture CAR T cells for the treatment of SCLC. He demonstrates the feasibility of this CAR T manufacturing platform and how this provides a blueprint for immediate clinical translation, overcoming the bottleneck of viral vector production.

This webinar is part of the “Translational T Cell Talks: Scaling for the Future” event hosted in collaboration with Scientist.com on June 11, 2024. View the rest of the talks and read the Q&A transcripts.